Industry Developments
South Korea
The halt of yet another clinical trial for a biosimilar of Roche's Rituxan (rituximab) highlights the regulatory issues biosimilars are currently experiencing. The delay will benefit...
2013-04-29Japan
Through their involvement in this growing trend, Shionogi, Daiichi Sankyo, Astellas Pharma, Takeda and Eisai can expect to reap huge reputational benefits, as well as access to knowledge...
2013-04-26Myanmar
We highlight the difficulty Myanmar will face in healthcare financing, given the country's high burden of communicable and non-communicable diseases. The situation is made worse by...
2013-04-25Japan
Emerging markets will drive industry growth. The importance of emerging markets to large multinational drugmakers cannot be overstated. BMI's Pharmaceutical Expenditure Model reveals...
2013-04-24Japan
A prescription medicine that treats a 'lifestyle' disease has been launched for the first time as an over-the-counter (OTC) drug in Japan. This is significant given that previous such...
2013-04-18Myanmar
Frontier markets offer drugmakers, medical device manufacturers and healthcare service providers substantial opportunities. Sales will be low initially and losses are possible for several...
2013-04-16China
BMI View: We maintain our positive outlook for the Chinese pharmaceutical market in 2013. Domestic pharmaceutical firms achieved strong revenue growth in 2012, in line with our bullish...
2013-04-09BMI View: Revenue earning opportunities for pharmaceutical and healthcare companies operating in the Asia Pacific region are largely driven by spending growth in developing countries....
2013-04-08
